Trial Profile
A biosimilar of rituximab versus innovator rituximab in patients with diffuse large B-cell lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 12 Jul 2012
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Pharmacokinetics
- 12 Jul 2012 New trial record
- 17 Jun 2012 Interim results presented at the 17th Congress of the European Haematology Association.